Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action

Malaysian Reserve

06-05-2025

NEW YORK, May 6, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ('Sana Biotechnology, Inc.' or the 'Company') (NASDAQ: SANA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146926&wire=4
SANA investors may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants' public statements were materially false and/or misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame, you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[e-mail]
Tel: [phone]
Fax: [phone]
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-sana-biotechnology-incsana-should-contact-levi–korsinsky-about-pending-class-action—sana-302446452.html
SOURCE Levi & Korsinsky, LLP